title: Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R.
abstract: Approximately 30% of chronic myeloid leukemia patients show initially no response to Imatinib, a potent inhibitor of BCR-ABL. This intrinsic resistance may be due to BCR-ABL-independent cell growth. Here we analysed the cytogenetic anomalies and the proteomic profiling in KCL22-S and KCL22-R, two Imatinib-sensitive and -resistant derivative cell lines of KCL22. A tetrasomy 8 and a non-reciprocal translocation +der(6)t(6;13)(p11.1;q12) were found only in KCL22-R as new evolved anomalies. Chromosome der(6)t(6;13) showed four variants differing in the chromatin content of 13q14-13qter including the retinoblastoma gene. Due to these sub-clones, approximately 65-79% of the Imatinib-treated KCL22-R cells showed a disomy and 21-35% a monosomy for 13q14. Imatinib removal reduced the main clone to approximately 20% in the benefit of the monosomic sub-clones. This was accompanied by an increased apoptosis rate and was revertible by Imatinib re-treatment. This effect may be connected with genes located in 13q14-qter. Proteomic profiling of the cell lines performed with ProteinChip technology (SELDI) revealed several differentially expressed proteins (n=45). In summary, we demonstrate here the complex changes on the cytogenetic and proteomic level which could be caused by Imatinib and the resistance resulting from it.
authors.affiliation: Core Unit Chip Application, Institute of Human Genetics and Anthropology, Jena, Germany.
authors.forename: Julia
authors.initials: J
authors.lastname: Rosenhahn
authors.forename: Anja
authors.initials: A
authors.lastname: Weise
authors.forename: Susanne
authors.initials: S
authors.lastname: Michel
authors.forename: Katrin
authors.initials: K
authors.lastname: Hennig
authors.forename: Isabell
authors.initials: I
authors.lastname: Hartmann
authors.forename: Jana
authors.initials: J
authors.lastname: Schiefner
authors.forename: Katrin
authors.initials: K
authors.lastname: Schubert
authors.forename: Thomas
authors.initials: T
authors.lastname: Liehr
authors.forename: Ferdinand
authors.initials: F
authors.lastname: von Eggeling
authors.forename: Ivan F
authors.initials: IF
authors.lastname: Loncarevic
mesh_terms: D000782:Aneuploidy; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis; D001549:Benzamides; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002896:Chromosomes, Human, Pair 6 / Q000235:genetics; D020732:Cytogenetic Analysis; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000378:metabolism*; D010879:Piperazines / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011506:Proteins / Q000032:analysis; D040901:Proteomics; D011743:Pyrimidines / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011506:Proteins; D011743:Pyrimidines; D000068877:Imatinib Mesylate